CAS: 1228108-65-3

Sabutoclax (BI-97C1)(BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM,

Sabutoclax is a small-molecule inhibitor, which is derived from the apogossypolone class. This compound functions by targeting the Bcl-2 family of proteins, which are critical regulators of apoptosis. Sabutoclax operates through binding to multiple anti-apoptotic Bcl-2 proteins, such as Bcl-2, Bcl-xL, and Mcl-1, thus disrupting their interaction with pro-apoptotic proteins. This disruption facilitates the induction of apoptosis in cancer cells, leading to cell death. Primarily investigated for its potential in oncology, Sabutoclax has shown activity in preclinical studies across various cancer types by effectively triggering apoptotic pathways. Its ability to bind multiple targets within the Bcl-2 family makes it a promising candidate for overcoming resistance mechanisms often encountered in cancer therapies. The agent’s potential to enhance the efficacy of existing treatments further underscores its relevance in combination therapeutic approaches. Researchers continue to explore its full therapeutic window, aiming to harness its apoptotic induction capabilities while minimizing off-target effects.

Sabutoclax